The pandemic is only a year old, but we already have multiple vaccines available to fight Covid-19 – including the vaccine developed by the team we are part of at the University of Oxford.
With our partner AstraZeneca, we have submitted both interim efficacy data and safety data for the vaccine to regulators across the world for independent scrutiny and approval. So far the vaccine has been approved for emergency use in the United Kingdom, India, Morocco, Argentina and El Salvador.
As well as being great news for getting us back to normal, this represents a phenomenal scientific achievement. Typically, developing a vaccine takes decades – but we have several available for Covid-19 after just 12 months. Here is how we managed this for the Oxford vaccine.
A head-start on development
Our vaccine works by delivering the genetic sequence of the SARS-CoV-2 spike protein to the body’s cells (the spike proteins are the distinctive structures that “crown” the…
